Racine IVF Unit, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Int J Gynecol Pathol. 2010 Jan;29(1):19-23. doi: 10.1097/PGP.0b013e3181ad1c52.
Transplantation of cryopreserved tissue from patients with cancer may carry the risk of reactivation or redissemination of micrometastases. This prospective study was conducted to evaluate the potential involvement of micrometastases in ovarian tissue in cancer patients. Ovarian biopsies were collected from patients who underwent ovarian tissue cryopreservation, in our IVF unit before chemotherapy between 2000 and 2008. Indications for cryopreservation included breast cancer (n=13), osteosarcoma (n=13), hematologic malignancies (n=13), uterine cervix carcinoma (n=2), endometrial carcinoma (n=1), colon cancer (n=1), and brain medulloblastoma (n=1). The samples were stained with hematoxylin and eosin, and examined histologically. Immunoperoxidase broad-spectrum cytokeratin staining was also performed on specimens from breast cancer patients. There were 44 patients (age range 5-40 yr) who yielded 40 specimens. No gross pathologic involvement was observed, and the histologic examination revealed normal histology with no evidence of metastases. Our findings showed that for the purpose of considering ovarian tissue cryopreservation in cancer patients, the likelihood of microscopic metastases within ovaries of normal appearance is apparently very low. Clarification of the actual risk of ovarian involvement and any subsequent risk of micrometastases and tumor reimplantation requires further investigation.
从癌症患者中移植冷冻组织可能会带来微转移灶再激活或再播散的风险。本前瞻性研究旨在评估癌症患者卵巢组织中微转移灶的潜在参与情况。在 2000 年至 2008 年期间，我们的 IVF 中心在化疗前对接受卵巢组织冷冻保存的患者进行了卵巢活检。冷冻保存的适应证包括乳腺癌（n=13）、骨肉瘤（n=13）、血液恶性肿瘤（n=13）、子宫颈癌（n=2）、子宫内膜癌（n=1）、结肠癌（n=1）和脑髓母细胞瘤（n=1）。对样本进行了苏木精和伊红染色，并进行了组织学检查。还对乳腺癌患者的标本进行了广谱细胞角蛋白免疫过氧化物酶染色。有 44 名患者（年龄 5-40 岁）产生了 40 个标本。未观察到大体病理受累，组织学检查显示正常组织学，无转移证据。我们的研究结果表明，为了在癌症患者中考虑卵巢组织冷冻保存，外观正常的卵巢中出现显微镜下转移灶的可能性显然非常低。需要进一步研究来明确卵巢受累的实际风险以及随后的微转移灶和肿瘤再植入的风险。
